|
gptkbp:instanceOf
|
antiviral drug
|
|
gptkbp:alsoKnownAs
|
gptkb:Sofosbuvir
|
|
gptkbp:approvalYear
|
2013
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:J05AX15
|
|
gptkbp:CASNumber
|
1190307-88-0
|
|
gptkbp:chemicalFormula
|
C22H29FN3O9P
|
|
gptkbp:combinationTherapy
|
gptkb:peginterferon_alfa
ribavirin
ledipasvir
velpatasvir
|
|
gptkbp:developedBy
|
gptkb:Gilead_Sciences
gptkb:Pharmasset
|
|
gptkbp:drugClass
|
nucleotide
|
|
gptkbp:eliminationHalfLife
|
0.4 hours (sofosbuvir), 27 hours (GS-331007 metabolite)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
PSI-7977
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Sovaldi
|
|
gptkbp:mechanismOfAction
|
inhibits HCV NS5B polymerase
|
|
gptkbp:metabolism
|
gptkb:GS-331007
|
|
gptkbp:patent
|
gptkb:Gilead_Sciences
|
|
gptkbp:pregnancyCategory
|
B1 (Australia)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
fatigue
headache
insomnia
|
|
gptkbp:usedFor
|
treatment of hepatitis C
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:DB09223
|
|
gptkbp:bfsLayer
|
5
|